C-Path's Critical Path for Duchenne Muscular Dystrophy Executive Director Ramona Belfiore-Oshan talks about the work DRSC is doing to accelerate Duchenne muscular dystrophy drug development.
SUBSCRIBE to C-Path's RU-vid Channel Now ►► / criticalpathinstitute
FOLLOW C-Path:
►LinkedIn: / c-path
►Facebook: / cpathinstitute
►Twitter: CP...
About Critical Path Institute
C-Path is an independent, nonprofit established in 2005 as a public-private partnership, in response to the FDA’s Critical Path Initiative. C-Path’s mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path’s global headquarters is located in Tucson, Arizona and C-Path’s Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit c-path.org.
#Duchenne #CPath #drugdevelopment
11 сен 2024